Evidence map›Paper›PMID 36873187›Full record

ArticleActa pharmaceutica Sinica. B2023

Photosensitive pro-drug nanoassemblies harboring a chemotherapeutic dormancy function potentiates cancer immunotherapy.

Jianjun Cheng, Haitian Zhao, Bin Li, Hua Zhang, Qianyu Zhao, Shiyao Fu, Ying Han, Weihong Lu, Jiahua Shi, Xin Yang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jianjun ChengSchool of Medicine and Health, Harbin Institute of Technology, Harbin 150001, China.
Haitian ZhaoSchool of Medicine and Health, Harbin Institute of Technology, Harbin 150001, China.
Bin LiAcademician Workstation, Jiangxi University of Chinese Medicine, Nanchang 330004, China.
Hua ZhangSchool of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin 150001, China.
Qianyu ZhaoSchool of Medicine and Health, Harbin Institute of Technology, Harbin 150001, China.
Shiyao FuSchool of Medicine and Health, Harbin Institute of Technology, Harbin 150001, China.
Ying HanSchool of Medicine and Health, Harbin Institute of Technology, Harbin 150001, China.
Weihong LuSchool of Medicine and Health, Harbin Institute of Technology, Harbin 150001, China.
Jiahua ShiKey Laboratory of Natural Medicine and Immune-Engineering of Henan Province, Henan University, Kaifeng 475004, China.
Xin YangSchool of Medicine and Health, Harbin Institute of Technology, Harbin 150001, China.
Harbin Institute of Technology · CNHenan University · CNJiangxi University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy combined with effective therapeutics such as chemotherapy and photodynamic therapy have been shown to be a successful strategy to activate anti-tumor immune responses for improved anticancer treatment. However, developing multifunctional biodegradable, biocompatible, low-toxic but highly efficient, and clinically available transformed nano-immunostimulants remains a challenge and is in great demand. Herein, we report and design of a novel carrier-free photo-chemotherapeutic nano-prodrug COS-BA/Ce6 NPs by combining three multifunctional components-a self-assembled natural small molecule betulinic acid (BA), a water-soluble chitosan oligosaccharide (COS), and a low toxic photosensitizer chlorin e6 (Ce6)-to augment the antitumor efficacy of the immune adjuvant anti-PD-L1-mediated cancer immunotherapy. We show that the designed nanodrugs harbored a smart and distinctive "dormancy" characteristic in chemotherapeutic effect with desired lower cytotoxicity, and multiple favorable therapeutic features including improved

Indexed as

Betulinic acidCancer immunotherapyChemotherapeutic dormancyNano-immunostimulantsNatural small moleculePhotodynamic therapyPro-drugSelf-assembly

Identifiers

PMID36873187
PMCPMC9978634
OpenAlexW4281723438

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.